



1
2 Supplementary Figure 1: Neuregulin 1 increases the growth of mammary organoids
3 compared to EGF. (a) Mammary epithelial cells were freshly isolated, embedded in
4 matrigel and exposed to culture medium containing Noggin (100ng/ml), EGF (100
5 ng/ml) or Neuregulin 1 (100ng/ml) for 15 days. The number of viable cells (Wst
6 assay) was evaluated (n=3, means±s.e.m.). *, $p < 0.05$, paired Student T test. (b)
7 Representative pictures of mammary organoids treated with culture medium
8 containing Noggin (100ng/ml), EGF (100 ng/ml) or Neuregulin 1 (100ng/ml) for 15
9 days. Scale bar, 50 μm .
10




11
 12 Supplementary Figure 2: Neuregulin 1 treated organoids contain distinct cell
 13 compartments. Mammary epithelial cells were cultured with 100 ng/ml Neuregulin 1
 14 and 100 ng/ml Noggin for 30 days. Organoids were fixed, embedded in paraffin and
 15 sectioned. Organoid sections were stained for p63, keratin 14 (K14), progesterone
 16 receptor (PR) and smooth muscle actin (SMA). Note the presence of p63+ SMA- cells
 17 (white arrows) in the basal cell layer. Counterstain, DAPI (blue).
 18




19
20
21
22
23
24
25


Supplementary Figure 3: Immunohistochemical detection of β -catenin in mammary organoids grown under Neuregulin 1 (100ng/ml) / Noggin (100ng/ml) (a), EGF (50ng/ml) / Noggin (100ng/ml) / R-spondin 1 (600ng/ml) (b) and Neuregulin 1 (100ng/ml) / Noggin (100ng/ml) / R-spondin 1 (100ng/ml) (c) culture conditions. Scale bar, 25 μ m.



50ng/ml
Neuregulin 1




100ng/ml
Neuregulin 1



200ng/ml
Neuregulin 1


26
27 Supplementary Figure 4: High concentrations of Neuregulin 1 promotes the growth of
28 mammary organoids compared to low concentrations of Neuregulin 1. Mammary
29 epithelial cells were freshly isolated, embedded in matrigel and exposed to culture
30 medium containing Noggin (100ng/ml) and increasing concentrations of Neuregulin 1
31 for 30 days. Scale bar, 100 μ m.
32




33
34
35
36
37

Supplementary Figure 5: Validation of antibodies used in this study on mouse mammary gland tissue.


Mouse IgG control



Rabbit IgG control




38
39 Supplementary Figure 6: Mammary organoid sections exposed to mouse IgG or rabbit
40 IgG control antibodies show no immunohistochemical staining. Scale bar, 25 μ m.
41




42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

Supplementary Figure 7: Mammary organoids treated with Neuregulin 1 can be maintained in culture for long-term. Mammary epithelial cells were freshly isolated, embedded in matrigel, exposed to culture medium containing Neuregulin 1 (100ng/ml) and Noggin (100ng/ml) and cultured for 75 days. Mammary organoids were then fixed and stained for selected markers. (a) Scale bar, 50 μ m. (b) Scale bar, 20 μ m. (c) Quantification of chromosome number in mammary organoids cultured for 75 days (n=11). Chromosomal spreads with 40 ± 1 chromosomes were considered normal. (d) Representative picture of metaphase chromosome spread that shows a normal number of chromosomes. (e) Expression of PR, RankL and Wnt4 following treatment with estrogen (E, 4ng/ml) or progesterone (P, 40ng/ml) for 4 hours. The gene expression was evaluated by quantitative RT-PCR. Data are expressed as fold change (vs untreated, n=3, means \pm s.e.m.). *, p < 0.05, paired Student T test.

MMTV-Wnt1 tumour tissue




Mammary organoids *in vitro*




69
70
71
72
73
74
75
76
77
78

Supplementary Figure 9: R-spondin 1 treated mammary organoids recapitulate MMTV-Wnt1 tumour tissue histology. Mammary epithelial cells were cultured with 600 ng/ml R-spondin 1, 50 ng/ml EGF and 100 ng/ml Noggin for 21 days. Organoids were fixed, embedded in paraffin and sectioned. Sections were stained with Hematoxylin and Eosin (H&E) and for basal markers (keratin-14, K14; p63; smooth muscle actin, SMA). In parallel, MMTV-Wnt1 driven mammary gland tumours were fixed, embedded in paraffin, sectioned and stained.




79
80
81
82
83
84
85
86
87
88
89
90
91
92

Supplementary Figure 10: Long-term culture of mammary organoids with EGF and high concentrations of R-spondin 1 is associated with chromosomal abnormalities. Mammary epithelial cells were freshly isolated, embedded in matrigel, exposed to culture medium containing EGF(50ng/ml), Noggin (100ng/ml) and R-spondin 1 (42.5 ng/ml) and cultured for 100 days (passaged 10 times). (a) Representative pictures of mammary organoids (scale bar, 100 µm). (b) Mammary organoids were fixed and stained for the basal markers p63 and keratin 14 (K14) and luminal markers progesterone receptor (PR) and keratin 8 (K8) (DAPI, blue) (scale bar, 50 µm). (c) Quantification of chromosome number in mammary organoids cultured for 100 days (n=26). Chromosomal spreads with 40±1 chromosomes were considered normal. (d) Representative picture of metaphase chromosome spread that shows an aberrant number of chromosomes.




93
 94 Supplementary Figure 11: Mammary organoids treated with EGF and high
 95 concentrations of R-spondin 1 can be maintained in culture for long-term. Mammary
 96 epithelial cells were freshly isolated, embedded in matrigel, exposed to culture
 97 medium containing EGF(50ng/ml), Noggin (100ng/ml) and R-spondin 1 (600 ng/ml)
 98 and cultured for 5 months. Mammary organoids were then fixed and stained for
 99 selected markers (scale bar, 50 μ m).
 100




101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113


Supplementary Figure 12: R-spondin 1 and Neuregulin 1 support the growth of karyotypically normal organoids that contain a robust basal cell population. Mammary epithelial cells were cultured with 100 ng/ml R-spondin 1, 100 ng/ml Neuregulin 1 and 100 ng/ml Noggin for 30 days. (a) Quantification of chromosome number in mammary organoids cultured for 30 days (n=11). Chromosomal spreads with 40 ± 1 chromosomes were considered normal. (b) Organoids were fixed, embedded in paraffin and sectioned. Organoid sections were co-stained for estrogen receptor (ER), progesterone receptor (PR), p63, keratin 14 (K14) and smooth muscle actin (SMA). Note the presence of p63+ SMA- cells (white arrows) in the basal cell layer. Counterstain, DAPI (blue).



114
 115 Supplementary Figure 13: R-spondin 1 supports Wnt signalling activation in
 116 mammary organoids. (a) Axin2-LacZ (Wnt reporter) mammary epithelial cells were
 117 freshly isolated, embedded in matrigel and exposed to culture medium containing
 118 Neuregulin 1 (100ng/ml), Noggin (100ng/ml) +/- R-spondin 1 (100 ng/ml) for 30
 119 days. Mammary organoids were then fixed and stained for β -galactosidase. (b) Axin2-
 120 LacZ (Wnt reporter) mammary epithelial cells were freshly isolated, embedded in
 121 matrigel and exposed to culture medium containing Neuregulin 1 (100ng/ml) and
 122 Noggin (100ng/ml) for 6 weeks. The culture medium was then supplemented with
 123 or without R-spondin 1 (100 ng/ml) for 6 days. Mammary organoids were fixed and
 124 stained for β -galactosidase. Scale bar, 50 μ m.
 125




126
 127 Supplementary Figure 14: Characterisation and identification of proliferating cells
 128 within mammary organoids under standard conditions, or following 24 hour treatment
 129 with steroid hormones. Mammary organoids were cultured with 2.6 ng/ml R-spondin
 130 1 (Peprotech), 100 ng/ml Neuregulin 1 and 100 ng/ml Noggin for 14 days. Where
 131 indicated, estrogen (4ng/ml), progesterone (40 ng/ml) or both hormones were added
 132 for the final 24 hours in culture. 10 μ M EdU was applied 2 hours prior to fixing, and
 133 fixed organoids stained for EdU and progesterone receptor (PR). Counterstain,
 134 Hoechst (blue). Scale bars, 50 μ m. White arrows indicate distinct examples of EdU
 135 positive, PR negative cells.
 136
 137




138
 139
 140
 141
 142
 143
 144
 145
 146
 147

Supplementary Figure 15: Histological characterisation of mammary organoids during development in culture. Mammary organoids were cultured with 2.6 ng/ml R-spondin 1 (Peprotech), 100 ng/ml Neuregulin 1 and 100 ng/ml Noggin for 3.5 days (a), 7 days (b) or 14 days (c). Organoids were fixed and stained for progesterone receptor (PR), keratin 8 (K8), estrogen receptor (ER), keratin 14 (K14), keratin 5 (K5), p63, smooth muscle actin (SMA), β -catenin and E-cadherin. Counterstain, hoechst (blue). Scale bars, 50 μ m.




148
 149
 150
 151
 152
 153
 154
 155

Supplementary Figure 16: R-spondin 1 alone does not promote the growth of mammary organoids. Mammary epithelial cells were cultured with R-spondin 1 (100 ng/ml), Neuregulin 1 (100 ng/ml) or both for 30 days. The number of viable cells (Wst assay) was then measured (n=3, means±s.e.m.). *, p<0.05, paired Student T test.




156
157
158
159
160
161
162
163
164
165
166
167

Supplementary Figure 17: Mammary cells from C57BL/6 mouse strain can form organoids with distinct luminal and basal cell compartments. Mammary epithelial cells were freshly isolated, embedded in matrigel and exposed to culture medium containing Neuregulin 1 (100ng/ml), Noggin (100ng/ml) and R-spondin 1 (100 ng/ml). (a) Representative pictures of mammary organoids cultured for 21 days. (b) After 30 days in culture, C57BL/6 mammary organoids were fixed and stained for the basal marker p63 and luminal markers progesterone receptor (PR) and estrogen receptor (ER) (DAPI, blue).




168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180

Supplementary Figure 18: Constitutive Wnt pathway activation increases organoid formation and size. Mammary epithelial cells were freshly isolated from a Tet-O- Δ N89 β -Catenin mouse line and embedded in matrigel. Cultures were treated with Neuregulin 1 (100 ng/ml) and Noggin (100 ng/ml) supplemented media alone, or additionally given R-Spondin 1 (R; 2.656 ng/ml), Doxycycline (D; 2 μ g/ml), or both in combination. (a) After 7 days, organoid number and average diameter were assessed using GelCountTM scanner and software from Oxford Optronix. Data are expressed as fold change (vs Neu, Nog only, n=3, means \pm s.e.m.). **, p < 0.01; ***, p < 0.001, ANOVA with Tukey's post-hoc comparison. (b) Representative pictures of mammary organoids cultured for 7 days under each condition. Scale bar, 100 μ m.




181
 182 Supplementary Figure 19: The Wnt signalling inhibitor IWP-2 decreases organoid
 183 forming efficiency and organoid diameter. Mammary epithelial cells were freshly
 184 isolated, embedded in matrigel and exposed to culture medium containing Neuregulin
 185 1 (100ng/ml), Noggin (100ng/ml), R-spondin 1 (2.656 ng/ml) and increasing
 186 concentrations of IWP-2. (a) After 14 days, the number and diameter of organoids
 187 was assessed using GelCount™ scanner and software from Oxford Optronix. Data are
 188 expressed as fold change (vs untreated, n=3, means±s.e.m.). **, p < 0.01; ***, p <
 189 0.001, ANOVA with Dunnett's post-hoc comparison. (b) Representative pictures of
 190 mammary organoids cultured 14 days in the presence of increasing concentrations of
 191 IWP-2. Scale bar, 100 μm.
 192



193
194


195 Supplementary Figure 20 The Wnt signalling inhibitor IWR-1 decreases organoid
196 forming efficiency and organoid diameter. Mammary epithelial cells were freshly
197 isolated, embedded in matrigel and exposed to culture medium containing Neuregulin
198 1 (100ng/ml), Noggin (100ng/ml), R-spondin 1 (2.656ng/ml) and increasing
199 concentrations of IWR-1. (a) After 14 days, the number and diameter of organoids
200 was assessed using GelCount™ scanner and software from Oxford Optronix. Data are
201 expressed as fold change (vs untreated, n=3, means±s.e.m.). **, p < 0.01; ***, p <
202 0.001, ANOVA with Dunnett's post-hoc comparison. (b) Representative pictures of
203 mammary organoids cultured 14 days in the presence of increasing concentrations of
204 IWR-1. Scale bar, 100 µm.

205





206
 207
 208
 209
 210
 211
 212
 213
 214
 215


Supplementary Figure 21: The Wnt signalling inhibitor IWP-2 induces loss of expression of PR in mammary organoids. Mammary epithelial cells were freshly isolated, embedded in matrigel and exposed to culture medium containing Neuregulin 1 (100ng/ml), Noggin (100ng/ml), R-spondin 1 (2.6565ng/ml) and increasing concentrations of IWP-2. After 14 days in culture, mammary organoids were fixed and stained for the luminal marker PR and basal marker p63 (counterstain, hoechst). Scale bar, 50 μm .




216
 217 Supplementary Figure 22: The Wnt signalling inhibitor IWR-1 induces loss of
 218 expression of PR in mammary organoids. Mammary epithelial cells were freshly
 219 isolated, embedded in matrigel and exposed to culture medium containing Neuregulin
 220 1 (100ng/ml), Noggin (100ng/ml), R-spondin 1 (2.656 ng/ml) and increasing
 221 concentrations of IWR-1. After 14 days in culture, mammary organoids were fixed
 222 and stained for the luminal marker PR and basal marker p63 (counterstain, hoechst).
 223 Scale bar, 50 μ m.
 224



225
 226 Supplementary Figure 23: Loss of ErbB3 or ErbB4 abrogates mammary organoid
 227 growth. Mammary epithelial cells were freshly isolated and infected with control
 228 shRNA (scrambled) or ErbB3 or ErbB4 shRNA lentiviruses. Organoids were fixed at
 229 day 10 in culture. (a) Representative images of organoids infected with lentivirus,
 230 where successful infection was indicated by GFP positivity. Scale bar, 100 μ m. (b)
 231 Organoid infection success was calculated as number GFP+ organoids/total number
 232 organoids. Data shown as mean \pm (n=3). (c) Average GFP+ organoid area was
 233 analysed using ImageJ. Data are expressed as % of scrambled control (mean \pm S.E.M,
 234 n=3). **, p<0.01, Kruskal-Wallis test.
 235




236
 237 Supplementary Figure 24: HGF supplementation increases organoid forming
 238 efficiency and organoid diameter. Mammary epithelial cells were freshly isolated,
 239 embedded in matrigel and exposed to culture medium containing Neuregulin 1
 240 (100ng/ml), Noggin (100ng/ml), R-spondin 1 (2.656 ng/ml) and increasing
 241 concentrations of HGF. (a) After 11 days, the number and diameter of organoids was
 242 assessed using GelCountTM scanner and software from Oxford Optronix. Data are
 243 expressed as fold change (vs untreated, n=3, means±s.e.m.). **, p < 0.01; ***, p <
 244 0.001, ANOVA with Dunnett's post-hoc comparison. (b) Representative pictures of
 245 mammary organoids cultured for 4, 8 and 11 days in the presence of increasing
 246 concentrations of HGF. Scale bar, 100 μ m.
 247




248
 249
 250
 251
 252
 253
 254
 255
 256

Supplementary Figure 25: HGF supplementation does not alter luminal markers localisation. Mammary epithelial cells were freshly isolated, embedded in matrigel and exposed to culture medium containing Neuregulin 1 (100ng/ml), Noggin (100ng/ml), R-spondin 1 (2.656 ng/ml) and increasing concentrations of HGF. After 14 days in culture, mammary organoids were fixed and stained for luminal markers progesterone receptor (PR) and keratin 8 and for the nuclear marker hoechst. Scale bar, 50 μ m.



257
 258 Supplementary Figure 26: HGF supplementation does not alter basal markers
 259 localisation. Mammary epithelial cells were freshly isolated, embedded in matrigel
 260 and exposed to culture medium containing Neuregulin 1 (100ng/ml), Noggin
 261 (100ng/ml), R-spondin 1 (2.656 ng/ml) and increasing concentrations of HGF. After
 262 11 days in culture, mammary organoids were fixed and stained for basal markers p63
 263 and keratin 5 and for the nuclear marker hoechst. Scale bar, 50 μ m.
 264



265
 266
 267
 268
 269
 270
 271
 272

Supplementary Figure 27: Cellular characterisation of mammary organoids originating from single $CD24^{\text{high}} Sca1^{-}$ cells. Single $CD24^{\text{high}} Sca1^{-}$ cells were cultured for 14 days with R-spondin 1 (2.6 ng/ml), Neuregulin 1 (100 ng/ml) and Noggin (100 ng/ml). Organoids were fixed and stained for luminal markers (progesterone receptor, PR; estrogen receptor, ER; keratin 8, K8) and basal markers (keratin 5, K5; keratin 14, K14; p63). Counterstain, hoechst (blue). Scale bars, 50 μm .

273 Supplementary Table 1: Composition of B27 supplement

274

Reagent	Supplier, catalog number	Concentration ($\mu\text{g/ml}$)
Albumin	Gift from Dr Tess Saltmarsh	2500
Catalase	Sigma-Aldrich, C41	2.5
Glutathione (reduced)	Sigma-Aldrich, G6013	1
Insulin	Sigma-Aldrich, I1882	4
Superoxide dismutase	Sigma-Aldrich, S5395	2.5
Holo-transferrin	Calbiochem, 616242	5
Triiodo-L-thyronine (T3)	Sigma-Aldrich, T6397	0.002
L-carnitine	Sigma-Aldrich, C7518	2
Ethanolamine	Sigma-Aldrich, E9508	1
D-galactose	Sigma-Aldrich, G0625	15
Putrescine	Sigma-Aldrich, P5780	16.1
Sodium selenite	Sigma-Aldrich, S9133	0.01435
Corticosterone	Sigma-Aldrich, C2505	0.02
Linoleic acid	Sigma-Aldrich, L1012	1
Linolenic acid	Sigma-Aldrich, L2376	1
α -tocopherol	Sigma-Aldrich, 95240	1
α -tocopherol acetate	Sigma-Aldrich, T3001	1
Biotin	Sigma-Aldrich, B4639	0.1

275

276

277 Supplementary Table 2: Composition of N2 supplement

278

Reagent	Supplier, catalog number	Concentration ($\mu\text{g/ml}$)
Holo-transferrin	Calbiochem, 616242	10 000
Insulin	Sigma-Aldrich, I1882	500
Putrescine	Sigma-Aldrich, P5780	1611
Sodium selenite	Sigma-Aldrich, S9133	0.52

279

280

281 Supplementary Table 3: Karyotype analysis of organoids grown under the 3 culture
 282 conditions for 1 month (early), 2.5 months (mid) and 4 months (late). Chromosomal
 283 spreads with 40 ± 1 chromosomes were considered normal.

	Nrg1			EGF/high R-spondin 1			Nrg1/low R-spondin 1		
	Analysed cells	Normal	Abnormal	Analysed cells	Normal	Abnormal	Analysed cells	Normal	Abnormal
Early	NA	NA	NA	7	5	2 (38)	11	10	1 (38)
					71%	29%		91%	9%
Mid	11	10	1	NA	NA	NA	15	13	2
		91%	9%					87%	13%
Late	NA	NA	NA	26	3	23	29	4	25
					12%	88%		14%	86%

284

285

286 Supplementary Table 4: Composition of immunofluorescence buffer

Reagent	Supplier, catalog number	Final % in PBS (Invitrogen)
Albumin	Gift from Dr Tess Saltmarsh	0.1
Triton X-100	Sigma-Aldrich, T9284	0.2
Tween 20	Sigma-Aldrich, P1379	0.05

287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308

309 Supplementary Table 5: Antibodies used in this study

Antigen	Source	Name/clone; Catalog number	Incubation and dilution
Keratin 5	Covance	Rabbit polyclonal, PRB-160P	O/N 4°C, 1/100
Keratin 14	Covance	Rabbit polyclonal, PRB-155P	O/N 4°C, 1/500
p63	Abcam	Mouse monoclonal (C-04), ab735	O/N 4°C, 1/40
SMA	Abcam	Rabbit polyclonal, ab5694	O/N 4°C, 1/200
Keratin 8	Abcam	Rabbit polyclonal, ab59400	O/N 4°C, 1/100
PR	Thermo Scientific	Rabbit monoclonal (SP2), RM-9102	O/N 4°C, 1/50
ER α	Dako	Mouse monoclonal (C-1D5), M7047	O/N 4°C, 1/100
β -catenin	Cell Signaling Technology	Rabbit monoclonal (6B3), 9582	O/N 4°C, 1/100
E-cadherin	Abcam	Mouse monoclonal, ab610182	O/N 4°C, 1/400
Ki-67	Millipore	Rabbit polyclonal, AB9260	O/N 4°C, 1/500
BrdU	Sigma-Aldrich	Mouse monoclonal (BU33), B8434	O/N 4°C, 1/500
NKCC1	Dr Jim Turner, NIH, Bethesda, MD	Rabbit polyclonal	O/N 4°C, 1/1000

310
311
312

313 Supplementary Table 6: Primers used in this study

314

Gene	Sequence	
	Forward	Reverse
ER α	ATGAAAGGCGGCATACGGAAAG	CACCCATTTTCATTTTCGGCCTTC
PR	GCTTGCATGATCTTGTGAAACAGC	GGAAATTCCACAGCCAGTGTCC
RankL	GCAGATTTGCAGGACTCGACT	CCCACAATGTGTTGCAGTT
Wnt4	GTCAGGATGCTCGGACAACAT	CACGTCTTTACCTCGCAGGA
B2M	CTTTCTGGTGCTTGTCTCACTG	AGCATTGGATTTCAATGTGAG
HPRT	CCTAAGATGAGCGCAAGTTGAA	CCACAGGACTAGAACACCTGCTAA
RPL13A	CACTCTGGAGGAGAAACGGAAAGG	GCAGGCATGAGGCAAACAGTC

315

316